BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31765478)

  • 1. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
    Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
    Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
    Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Blood Res; 2022 Mar; 57(1):59-68. PubMed ID: 35256550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
    Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
    Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.
    Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Shin KS; Jo DY
    Intern Med; 2022 Dec; 61(23):3483-3490. PubMed ID: 35527026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
    Fisher DAC; Fowles JS; Zhou A; Oh ST
    Front Immunol; 2021; 12():683401. PubMed ID: 34140953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
    Shrestha R; Giri S; Armitage JO; Bhatt VR
    Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y; Lee JO; Bang SM
    J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
    Hansen IO; Sørensen AL; Hasselbalch HC
    Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
    Li Y; Zhang XY; Han J; Wang L
    Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
    Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
    Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.